Lupin’s subsidiary -- Lupin Pharma has entered into partnership with Endoceutics, a women’s health focused innovative Canadian biotech company, to commercialize Intrarosa in Canada. Intrarosa is Endoceutic’s flagship product indicated for the treatment of postmenopausal vulvovaginal atrophy offered as a vaginal ovule containing 6.5 mg of Prasterone. It is estimated that over 50% of postmenopausal women suffer from the symptoms of vulvovaginal atrophy and that less than 10% of these women are treated with prescription medicines.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
